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Introduction
Rhabdomyosarcoma (RMS) is the most 
common soft-tissue sarcomas (STS) and the 
third most common solid extracranial tumor in 
children.1,2 Incidence of RMS in India accounts 
for around 1 to 4.5%  of all malignancies 
in children.3 Each year, approximately 350 
children are diagnosed with RMS in the United 
States,4 while in Jakarta, Indonesia, the study 
has shown that there are only 44 RMS cases 
in 8-years time and 11 RMS cases in 4 years 
at Dr. Cipto Mangunkusumo General Hospital 
and Dharmais Cancer Hospital, respectively.5,6
RMS is originated from embryonic 
mesenchyme that differentiates into striated 
or skeletal muscle.7 Therefore, RMS could rise 
anywhere throughout the human body where 
there is skeletal muscle or not such as the 
urinary bladder, bile ducts, etc.8 The symptoms 
are not always in the form of a lump. The 
clinical presentations depend on the primary 
location of the tumor where the majority of 
symptoms are related to the compression of 
local structures by the masses and may cause 
organ-specific symptoms.8 This non-specific 
pattern could complicate RMS detection and 
cause a diagnostic delay.1,9 Survival rate of 
children with RMS has increased from 25% 
in 1970 to 70% in 2001. However, mortality 
rates remain significantly higher in developing 
countries than in developed countries. This 
may also be attributable to the high frequency 
of detection and diagnostic delays among 
them.10
Currently, research and literature 
studies on the clinical characteristics of 
rhabdomyosarcoma in Indonesia are very 
limited. This study aimed to describe the 
clinical characteristics of rhabdomyosarcoma 




Background: Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcomas (STS) in children. 
Even though the survival rate has increased, the mortality rates remain significantly higher in 
developing countries due to delay in diagnosis contributed by its diverse and clinical manifestations. 
This study aimed to describe the clinical characteristics of RMS patients at the Department of Child 
Health, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
Methods: A descriptive cross-sectional retrospective study was conducted using a total sampling 
method on medical records of RMS patients aged ≤ 18-year-old during a 4-year period (2015-2018). 
Data on patient demographics, clinical manifestations, biopsy procedure, histopathological subtype, 
tumor size, primary site, pre-treatment staging, and treatment were reviewed and presented.
Results: Of 30 data retrieved, male (57%), aged 1 to 5-year-old (47%), and diagnosed through 
open biopsy (63%) comprised the majority of the patients. More than half of the patients came with 
advanced stage of the disease (80%) and were treated with chemotherapy (83%). Most RMS patients 
had a tumor located in the head and neck region (40%) with a size of >5 cm (70%) and embryonal 
subtypes (43%). The remaining patients experienced alveolar subtype (17%), spindle cell subtype 
(13%), and unknown subtype (27%) of RMS.
Conclusions: Children with a tumor in the head and neck region should be suspected as 
rhabdomyosarcoma, as there are various clinical characteristics of RMS in children found in this study.
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Methods
This study was performed at Dr. Hasan 
Sadikin General Hospital, a tertiary hospital 
in Bandung, West Java, Indonesia using a 
descriptive cross-sectional design and total 
sampling method. A retrospective analysis 
was performed on medical records of children 
(n=40) who were diagnosed with RMS through 
biopsy during the period of 2015–2018. 
Incomplete medical records were excluded 
(n=10). The medical records were reviewed 
for patient identities, clinical manifestations, 
biopsy procedure, histopathological subtype, 
tumor size, primary site, TNM staging, and 
treatment. 
Tumor size had been used in evaluation 
for pre-treatment TNM staging according 
to Children’s Oncology Group Soft-Tissue 
Sarcoma Committee’s (COG-STS).11 The 
histological subtype classification used in this 
study was based on the newest classification 
Table 1 Clinical Manifestations of Children with Rhabdomyosarcoma
Clinical Manifestations n %
Painless mass/lump/swelling 24 80
Local pain 3 10
Proptosis 3 10
Ophthalmoplegia 1 3
Spontaneous bleeding 3 10
Epistaxis 1 3
Nasal congestion 1 3
Vomiting 1 3
Urinary obstruction 1 3
Convulsions 1 3
Pale 2 7
Limb weakness 2 7
Figure Age of Children with Rhabdomyosarcoma
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Table 2 Clinical Characteristics of Childhood Rhabdomyosarcoma 
Clinical Characteristics N %
Gender
     Male 17 57
     Female 13 43
Age (years old)
     ≤1 2 7
     >1–5 14 47
     >5–10 3 10
     >10–15 6 20
     >15–18 5 17
Biopsy procedure
     Open biopsy 19 63
     FNAB 11 37
Tumor size
     ≤5 cm 6 20
     >5 cm 21 70
     Not specified 3 10
Histopathological subtype
     Embryonal 13 43
     Alveolar 5 17
     Spindle cell 4 13
     Not specified 8 27
Primary site
     Head and neck 12 40
     Trunk 5 17
     Urogenital tract 5 17
     Extremities 8 27
TNM Staging
     II 1 3
     III 6 20
     IV 18 60
     Not specified 5 17
Treatment
     Operation 1 3
     Chemotherapy 14 47
     Operation-Chemotherapy 10 33
     Operation-Radiation 1 3
     Chemotherapy-Radiation 1 3
     Not given 3 10
Note: FNAB= fine-needle aspiration biopsy
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from WHO (2013).12 Pre-treatment staging 
used a modified TNM system based on the 
primary site, either favorable or unfavorable 
site.7
This study was approved by the Research 
Ethics Committee of Universitas Padjadjaran 
and Dr. Hasan Sadikin General Hospital. 
Further acknowledgment had been received 
by the Department of Child Health and the 
Department of Anatomical Pathology Dr. 
Hasan Sadikin General Hospital. The data 
collected were analyzed using descriptive 
statistics and then presented by using tables 
and charts (Microsoft® Excel 2016 and IBM® 
SPSS® version 20).
Results
A total of 30 children with confirmed RMS by 
biopsy were included during the 4-year study 
period. The median aged was 5 years old 
(range; 9 months to 18 years old). The highest 
incidence occurred in the age group of 1-5 
years (Figure). Male patients outnumbered 
female patients with M:F ratio 1.3:1. Patient 
demographics and tumor characteristics were 
summarized in Table 2. While the majority of 
the patients complained about a painless mass 
in their body, some patients came with other 
signs related to the primary site (Table 1).
Tumor size was assessed in 27 patients 
only, of whom 21 patients with tumor >5 cm. 
Biopsy was performed in open biopsy (n=19; 
63%) or fine-needle aspiration biopsy (11; 
37%). Tumor size had been used in evaluation 
for pre-treatment TNM staging According to 
the COG-STS Committee’s,
Of embryonal types (n=12), 3 patients had 
botryoid subtype of embryonal. Interestingly, 
the pleomorphic subtype was not found in this 
study. The histological subtype classification 
used in this study was based on the newest 
classification from WHO (2013).
More than half of the patients (57%) had a 
tumor in an unfavorable site. Tumor located 
in the facial, orbital, nose, lip, and neck were 
included in the head and neck group. Tumor 
in upper extremity was more dominant than 
lower extremity that counted in 75% of the 
patients. Tumor in extremities was most 
common in the age group 10–15 years. Tumor 
located in the intraabdominal and vertebrae 
were included in the trunk group while tumor 
in the bladder, testis, vulva, and vagina was 
included in the urogenital group.
Only 25 out of 30 children’s staging 
were identified. Of the 27 patients in whom 
treatment was initiated, the vast majority of 
the patients were treated with chemotherapy 
(83%) where 47% of them with chemotherapy 
only and the rest with combination therapy. 
Around 67% of children who had surgical 
resection had tumors >5 cm. Three patients 
died before giving any kind of therapy in the 
care center. Pre-treatment staging used a 
modified TNM system based on the primary 
site, either favorable or unfavorable site.
Discussions
The results of this study showed more male 
(54.05%) Rhabdomyosarcoma (RMS) is the 
most common soft-tissue sarcomas (STS) in 
children, included in the top 10 most common 
malignancies. Nevertheless, RMS incidence is 
relatively rare.7 In our center, there were only 
30 RMS children during the 4 years period. The 
median age is 5 years old or about 59.5 months. 
This finding is similar to a study conducted in 
China13 showing a median age of 61.5 months. 
In our study, most of the children (63%) aged 
below 10 years and the highest age-adjusted 
incidence in the category of aged 1–5 years, 
similar to a various studies published earlier.6,7 
Male patients outnumbered female patients 
with M:F ratio 1.3:1. This finding also similar 
to the previous studies, that consistently 
showed a gender differential incidence of 
child health cancer worldwide with M:F ratio 
around 1.2:1.13,14
Swelling or lump is the main presenting 
symptom in this study. This result is in 
accordance with a study in Sub-Saharan 
Africa10 showing that all the children have 
presented with swellings, while more than half 
of the patients in Romania1 presented with 
swelling in varying sites. Some of the additional 
symptoms may result from the compression 
of local structures by the masses.8 This often 
vague and non-specific symptom may cause a 
delay in the admission of these children to the 
care center, leading to the advanced stage of 
the disease.10
The diagnosis of RMS usually has been 
preferably performed by direct open biopsy.8 
An adequate biopsy sample is critical for an 
accurate biopsy, hence, fine needle aspiration 
biopsy (FNAB) is not recommended However, 
in this research study, an open biopsy was 
conducted to about 63% of the patients and 
the rest used FNAB similar to another study 
in Jakarta.6 The FNAB is a fast, highly safe, and 
effective method, therefore, FNAB is still used 
for the detection of carcinoma. FNAB is less 
expensive than open biopsy, does not require 
anesthesia, and also less traumatic, hence, it 
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could save more time and money, and also more 
convenient for the patient. Nonetheless, open 
surgical biopsy provided a more definitive 
diagnostic histology than FNAB.15 
A histologic subtype can be observed from 
biopsy samples microscopically. The most 
common subtype in this study is embryonal 
RMS, followed by alveolar and spindle cells. 
This result is quite similar to the findings from 
East Egypt and China that showed embryonal 
is the most frequent histopathologic subtype 
followed by alveolar and spindle cell though 
with quite different numbers.16,17 Plemorphic 
subtype has not been found in this research 
because it is really rare to occur in children 
and more common in adult patients.18 
Interestingly, there are patients with an 
unknown subtype of RMS. This is evidence 
that some tumors can not be characterized by 
the pathologist.18
The size of the tumor can only be party 
assessed since the tumor is in the unreachable 
location. The majority of the patients had 
tumors >5 cm.1,17 Around 70% of the patients 
with tumor >5 cm passed away. This high 
mortality may be caused by patient delays 
in seeking medical care that is influenced by 
socioeconomic status and education degree 
of the parents. This delay could slow down 
the establishment of the diagnosis which is 
proven to be related to the increasing size of 
the tumor.9 Education for the community and 
medical personnel is important to increase 
alertness for RMS to further improve the 
prognosis.
Rhabdomyosarcoma may occur in any 
anatomic location of the body. In this study, we 
have identified the most frequent primary sites 
are head and neck followed by extremities, 
then the trunk and urogenital tract as known.19 
However, another study in China has shown 
different primary sites with the genitourinary 
system is the most frequent site, followed 
by head and neck, then extremities.17 These 
differences may be caused by age range 
prevalent in each study. 
In this study, only 27 out of 30 patients were 
given treatment. Almost half of the patients 
(47%) only had chemotherapy while 33% 
had chemotherapy combined with surgical 
resection. Similar to the study in Jakarta, only 
41% had chemotherapy, while 39% had a 
combination of chemotherapy and surgical 
resection.6 The majority of the patients who 
came to the care center were in the advanced 
stages.1,6,20 This may be related to the low 
socioeconomic status, educational background 
of the parents, and other causes. Unfortunately, 
in this study, neither socioeconomic status 
nor education degree has been noted. This 
limitation may lead to further exploration. 
To conclude, children with a tumor in the 
head and neck region should be suspected as 
rhabdomyosarcoma. There are various clinical 
characteristics similar to the results of previous 
studies around the globe. Interestingly, late 
presentation is commonly seen; therefore, 
public health awareness and promotion are 
urgently needed. 
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